Skip to main content
Clinical Trials/CTIS2024-511679-14-00
CTIS2024-511679-14-00Active, not recruitingPhase 1

Improving outcome in subarachnoid hemorrhage with nadroparin

Amsterdam UMC Stichting0 sites100 target enrollmentStarted: May 24, 2024Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Status
Active, not recruiting
Enrollment
100

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Ages
18 to 65+ (—)
Sex
All

Inclusion Criteria

  • SAH confirmed by CT or lumbar puncture with the causative aneurysm confirmed by CT-A and/or DSA, Coiling of the causative aneurysm within 72 hours of initial SAH, Informed consent before the first scheduled administration of the study medicine, Adult age (=18 years)

Exclusion Criteria

  • Stent-assisted coiling, Use of anticoagulant or dual antiplatelet medication post-coiling for other reasons, Incomplete aneurysm occlusion/partial coiling, Intraparenchymal hemorrhage, Pregnancy, Contra-indications for LMWH: oPrevious history of history of heparin-induced thrombocytopenia o(Suspicion of) active arterial or venous bleeding oPrevious history of hemorrhagic diathesis due to coagulation disorders (with the ex-ception of disseminated intravascular coagulation) oSevere hypertension: uncontrolled hypertension with a MAP > 135mmHg oPrevious history of hypertensive or diabetic retinopathy oPrevious history of active infectious endocarditis oSevere renal impairment (creatinine clearance <30 mL / min), No proficiency of Dutch or English language, Proven and active COVID-19 infection

Investigators

Similar Trials